DXCM

DexcomNASDAQ · Health Care Equipment · Health Care

Previous close

82.29

Change

+2.36 / +2.95%

FinDog View

Bullish

52-Week Range ?

54.11 – 92.59

P/E (TTM) ?

30.2

Forward P/E ?

29.8

Based on consensus earnings for the next 12 months

Market Cap

$31.3B

−4.64%

S&P 500 −0.91% over same period

Volume / Avg Volume

8.6M / 5.7M

1.51× average

Latest earnings analysisFY2026 Q2Reported 2026-07-30

Dexcom Q2 2026: revenue up 13.1%, EPS $0.64, guidance midpoint nudged up

Dexcom's second quarter was a clean beat: revenue of $1.3084 billion grew 13.1% and gross margin jumped to 63.4%, with GAAP EPS of $0.64 ahead of the $0.6229 consensus. The raised full-year revenue midpoint moved only $10 million, so the real news is margin, not top-line ambition. Read the guidance and balance-sheet sections before the headline growth number.

Read the full analysis →

Revenue$1.31BYoY +13.10%

EPS (non-GAAP)$0.70Beatest. $0.62

Next-quarter revenue guidance$5.21B ±0.67%YoY +298.60%

Next-day move+11.95%

Price History

Closing price · USD1M 6M 1Y 5Y

Historical P/E

Close ÷ trailing four-quarter EPS · Period median 33.81M 6M 1Y 5Y

Recent Earnings

Click to read the FinDog analysis

Period	Reported	Revenue	EPS Actual / Est.	Next-Day Move	Analysis
FY2026 Q2 Quarter ended 2026-06	2026-07-30	$1.3B	0.70 / 0.62	+11.95%	Read analysis →
FY2026 Q1 Quarter ended 2026-03	2026-04-30	$1.2B	0.56 / 0.48	+3.02%	Pending
FY2025 Q4 Quarter ended 2025-12	2026-01-12	$4.7B	0.68 / 0.48	−1.03%	Pending
FY2025 Q3 Quarter ended 2025-09	2025-10-30	$1.2B	0.61 / 0.58	−14.63%	Pending
FY2025 Q2 Quarter ended 2025-06	2025-07-30	$1.2B	0.48 / —	−9.31%	Pending
FY2025 Q1 Quarter ended 2025-03	2025-05-01	$1.0B	0.27 / —	+16.17%	Pending

Next Earnings

Date and consensus from the earnings calendar; the analysis is generated automatically after the releaseEarnings Calendar →

Report date

2027-02-10

in 101 days · After hours

Consensus EPS

$0.75

Last quarter EPS $0.70

Avg. next-day move over the last 6 reports

±9.4%

Decision Panel

Trends · Valuation · Earnings reaction · Guidance credibility — all from company filings and market data

Valuation

P/E is at percentile 5 of its 5-year rangeCheap

5-year range 30.2 – 130.7 · Median 48.4

Last 4 quarters: $713M in buybacks + $0 in dividends, 2.28% of market cap combined

P/E (TTM)

30.2

P/B

11.5

P/S

6.1

PEG

1.29

Earnings Reaction

Over the last 6 reports, the stock moved ±9.4% on average on the first trading day after, rising 3 times

Most recent +11.95%

Volatility & Correlation

1-year beta 0.58 · Correlation with S&P 500 0.18Low beta

Annualized volatility 40% vs. 13% for the S&P 500

Insider Trading

View all →

Last 90 days · Open-market buys and sells by officers and directors · Amounts in USD millions

Buy 0 · $0.00MSell 13 · $4.9MNet selling $4.9M

10-27Stern SadieEVP Chief People & Culture OffSell$0.20M2,565 shares · Avg price 78.62
10-15Brown Michael JonEVP Chief Legal Compliance OffSell$0.15M1,700 shares · Avg price 85.48
09-28Stern SadieEVP Chief People & Culture OffSell$0.22M2,565 shares · Avg price 86.15
09-15Brown Michael JonEVP Chief Legal Compliance OffSell$0.14M1,700 shares · Avg price 84.04
09-15AUGUSTINOS NICHOLASDirectorSell$0.55M6,539 shares · Avg price 84.04
09-14AUGUSTINOS NICHOLASDirectorSell$0.13M1,550 shares · Avg price 84.02
09-10Sylvain Jereme MEVP, Chief Financal OfficerSell$0.30M3,638 shares · Avg price 83.27
08-27Stern SadieEVP Chief People & Culture OffSell$0.23M2,565 shares · Avg price 88.37

Multi-Quarter Financial Trends

View all quarters →

Last 12 quarters · As reported by the company

Quarter	Revenue ($B)	YoY	Gross Margin	Operating Income ($B)	Net Income ($B)	Free Cash Flow ($B)	EPS
FY2026 Q3	1.34	+11.2%	64.3%	0.33	0.28	0.27	0.72
FY2026 Q2	1.31	+13.1%	63.4%	0.32	0.25	0.18	0.64
FY2026 Q1	1.19	+15.0%	62.9%	0.26	0.20	0.45	0.51
FY2025 Q4	1.26	+13.1%	62.9%	0.32	0.27	0.19	0.67
FY2025 Q3	1.21	+21.6%	60.5%	0.24	0.28	0.58	0.70
FY2025 Q2	1.16	+15.2%	59.5%	0.21	0.18	0.21	0.45
FY2025 Q1	1.04	+12.5%	56.9%	0.13	0.11	0.10	0.27
FY2024 Q4	1.11	+7.6%	58.9%	0.19	0.15	0.18	0.37
FY2024 Q3	0.99	+2.0%	59.7%	0.15	0.13	0.09	0.34
FY2024 Q2	1.00	+15.3%	62.4%	0.16	0.14	0.21	0.35
FY2024 Q1	0.92	+24.2%	61.0%	0.10	0.15	0.15	0.36
FY2023 Q4	1.03	+26.9%	63.5%	0.22	0.26	0.08	0.61

Peers

Largest by market cap in the sector · Latest quarterView Health Care sector →

Ticker	Company	Market Cap	P/E	Revenue YoY	Gross Margin	1M	View
DXCM	Dexcom	$31.3B	30.2	+11.2%	64.3%	−4.64%	Bullish
LLY	Lilly (Eli)	$1.34T	50.2	+38.6%	83.9%	+22.51%	Bullish	Compare
JNJ	Johnson & Johnson	$666B	41.3	+5.9%	68.1%	+3.20%	Bullish	Compare
ABBV	AbbVie	$522B	81.4	+10.2%	74.7%	+12.73%	Bullish	Compare
UNH	UnitedHealth Group	$367B	23.0	+0.4%	88.1%	+10.87%	Bullish	Compare
MRK	Merck & Co.	$371B	117.2	+5.1%	73.5%	+2.90%	Neutral	Compare
TMO	Thermo Fisher Scientific	$258B	36.4	+9.1%	—	+3.25%	Neutral	Compare
AMGN	Amgen	$254B	28.5	+9.5%	72.0%	+10.56%	Bullish	Compare
GILD	Gilead Sciences	$213B	—	+6.8%	81.1%	+14.51%	Neutral	Compare

Earnings Preview · Reports 10-29

Dexcom Q3 preview: revenue trend and full-year guidance in focus

Whether revenue keeps last quarter's 13.1% year-over-year growth and nears 1.31 billion yuan
Whether gross margin holds near 63.4% and expenses stay in line
Progress on the 5.18–5.25 billion yuan full-year revenue guidance and FX impact

No consensus EPS detail beyond the 0.6866 figure; last quarter revenue was 1.31 billion yuan, up 13.1% year over year, with EPS of 0.64; in July the company guided full-year revenue to 5.18–5.25 billion yuan.

Over the past 6 earnings reports, the stock moved ±10.4% on average, rising 4 times, with the latest up 12%.

Watch out for：Higher-than-expected second-half expenses or inventory digestion could pressure margins.

The View in One Line

Q2 revenue up 13.1%, EPS $0.7 beat $0.62, gross margin 63.4%, full-year guidance raised; fundamentals clearly improving.

Updated 2026-10-30

View History

09-16Neutral → Bullish
Q2 revenue up 13%, EPS 0.7 beat expectations, gross margin 63.4%, raised full-year guidance; clear fundamental improvement and strong execution.

Notable Institutional Holders

Renaissance Technologies$110MAdded +3%
Citadel Advisors · Ken Griffin$81.6MReduced −42%
Bridgewater Associates · Ray Dalio$27.0MAdded +187%

As of 2026-06-30

ETFs holding it

XLV Health Care Select Sector SPDR Fund0.46%
RSP Invesco S&P 500 Equal Weight ETF0.21%
JEPQ JPMorgan Nasdaq Equity Premium Income ETF0.19%
QQQ Invesco QQQ0.15%
QQQM Invesco NASDAQ 100 ETF0.14%
SCHG Schwab U.S. Large-Cap Growth ETF0.13%
QUAL iShares MSCI USA Quality Factor ETF0.11%
VUG Vanguard Growth ETF0.11%

Weights estimated at latest prices

Key Events

10-29Capital Actions
Dexcom Approves Up to $1 Billion Share Repurchase Program
Dexcom's board approved a share repurchase program of up to $1.0 billion of common stock, ending no later than December 31, 2027.Source ↗
09-14Management Change
Dexcom CFO Sylvain Also Named COO
Dexcom announced on September 14, 2026 that CFO Jereme Sylvain was promoted to Executive Vice President, Chief Operating Officer and Chief Financial Officer, with a salary of $767,000.Source ↗
09-10Management Change
Dexcom Appoints Glenn Boehnlein to Board
On September 10, 2026, Dexcom expanded its board to 13 members, appointing Glenn S. Boehnlein as an independent director, who received restricted stock units valued at $500,000.Source ↗
05-28Governance
DexCom Annual Meeting Passes Proposals Including Director Elections
At the May 27, 2026 annual meeting, shareholders elected 12 directors, ratified Deloitte as 2026 auditor, and passed the advisory executive compensation vote.Source ↗
05-15Capital Actions
Dexcom Launches $1 Billion Stock Buyback Program
Dexcom's board approved a stock repurchase program of up to $1 billion through June 30, 2027, and terminated its prior plan with $250 million remaining.Source ↗

Key Financial Trends

Quarterly Revenue ($B)1.3

Gross Margin64.3%

Free Cash Flow ($B)0.3